tiprankstipranks
Trending News
More News >
Biovica International AB Class B (DE:9II)
FRANKFURT:9II

Biovica International AB Class B (9II) Price & Analysis

Compare
1 Followers

9II Stock Chart & Stats

€0.02
-€0.05(-28.13%)
At close: 4:00 PM EST
€0.02
-€0.05(-28.13%)

9II FAQ

What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was €0.01 and its highest was €0.20 in the past 12 months.
    What is Biovica International AB Class B’s market cap?
    Biovica International AB Class B’s market cap is €12.80M.
      When is Biovica International AB Class B’s upcoming earnings report date?
      Biovica International AB Class B’s upcoming earnings report date is Dec 18, 2025 which is in 4 days.
        How were Biovica International AB Class B’s earnings last quarter?
        Biovica International AB Class B released its earnings results on Sep 11, 2025. The company reported -€0.01 earnings per share for the quarter, missing the consensus estimate of -€0.01 by >-€0.001.
          Is Biovica International AB Class B overvalued?
          According to Wall Street analysts Biovica International AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Biovica International AB Class B pay dividends?
            Biovica International AB Class B does not currently pay dividends.
            What is Biovica International AB Class B’s EPS estimate?
            Biovica International AB Class B’s EPS estimate is >-0.01.
              How many shares outstanding does Biovica International AB Class B have?
              Biovica International AB Class B has 275,289,060 shares outstanding.
                What happened to Biovica International AB Class B’s price movement after its last earnings report?
                Biovica International AB Class B reported an EPS of -€0.01 in its last earnings report, missing expectations of -€0.01. Following the earnings report the stock price went down -27.027%.
                  Which hedge fund is a major shareholder of Biovica International AB Class B?
                  Currently, no hedge funds are holding shares in DE:9II

                  Company Description

                  Biovica International AB Class B

                  Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

                  Biovica International AB Class B (9II) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alzinova AB
                  Biosergen AB
                  Nanologica AB
                  Lipigon Pharmaceuticals AB
                  NextCell Pharma AB
                  Popular Stocks